- 标题
- 摘要
- 关键词
- 实验方案
- 产品
-
Intraoperatieve detectie van het heldercellig niercelcarcinoom met 111In-girentuximab-IRDye800CW: proof-of-principlestudie; Intraoperative detection of clear cell renal cell carcinoma with 111In-girentuximab-IRDye800CW: proof of principle study;
摘要： The aim of this study is to show the feasibility and safety of CAIX-targeted dual-modality imaging in ccRCC. Seven days before partial or radical nephrectomy, patients were injected with 100MBq 111In-girentuximab-IRDye800CW (5–50 mg). After 4 days a SPECT/CT was obtained. After 7 days surgery was performed with the use of intraoperative gamma probe detection and fluorescence imaging. Fifteen patients were included, of which three had a CAIX-negative tumor. No study-related serious adverse events were observed. All ccRCC were visualized on the SPECT/CT scan and localized by intraoperative gamma probe detection (mean T:N ratio 2.5 ± 0.8), while mean T:N ratios were 1.0 ± 0.1 in CAIX-negative tumors. All ccRCC were hyperfluorescent and in one patient fluorescence imaging revealed a positive surgical margin. Conclusion: Tumor-targeted dual-modality imaging using 111In-girentuximab-IRDye800CW is safe and can be used for intraoperative ccRCC detection.
关键词： carbonic anhydrase IX,image-guided surgery,girentuximab,renal cell carcinoma
更新于2025-09-23 15:22:29
-
Fluorine-18 click radiosynthesis and MicroPET/CT evaluation of a small peptide-a potential PET probe for carbonic anhydrase IX
摘要： Carbonic anhydrase IX (CA IX) is the first carbonic anhydrase found to be associated with cancer that is over-expressed in a variety of human solid tumors. As a surrogate marker for hypoxia, the expression of CA IX is strongly upregulated in hypoxic tumors by hypoxia and hypoxia-inducible factor 1a (HIF-1a). In our pursuit of a CA IX-specific PET probe, we designed and synthesized a peptide-based CA IX imaging probe by the efficient click reaction of 1,3-dipolar cycloaddition of terminal alkynes and organic azides. The probe 18F-CA IX-P1-4-10 was obtained with a radiochemical yield of 35-45% (n = 5) and radiochemical purity of >99% in 70-80 min (HPLC purification time included). 18F-CAIX-P1-4-10 had good stability in phosphate buffered saline (PBS), but about 51% peptide degradation was detected in new-born calf serum (NBCS) after incubation. Preliminary microPET/CT experiments demonstrated a specific uptake of 18F-CA IX-P1-4-10 in HT29 tumor and the uptake of 18F-CA IX-P1-4-10 was blocked by peptide CA IX-P1-4-10-Yne pretreatment. Immunohistochemical staining and western blotting studies confirmed the HT29 tumor was CA IX-positive which further proved tumor accumulation of 18F-CA IX-P1-4-10 was correlated with CA IX expression. The results suggest that 18F-CA IX-P1-4-10 is a promising PET tracer for the specific imaging of CA IX-expressing tumors at the molecular level.
关键词： peptide,tumor hypoxia,18F-labeling,Carbonic anhydrase IX,PET imaging
更新于2025-09-19 17:15:36